- Home
- PGEN
PGEN
Precigen Inc.
as 04-01-2025 3:41pm EST
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GERMANTOWN |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $7.33 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $2.17 | Next Earning Date: | 03-19-2025 |
| Revenue: | $3,925,000 | Revenue Growth: | -36.95% |
| Revenue Growth (this year): | 459.24% | Revenue Growth (next year): | 651.03% |
Latest Precigen Inc. News
PGEN Breaking Stock News: Dive into PGEN Ticker-Specific Updates for Smart Investing
GuruFocus.com
11 days ago
Precigen Inc (PGEN) Q4 2024 Earnings Report Preview: What To Expect
PR Newswire
14 days ago
Precigen Reports Full Year 2024 Financial Results and Business Updates
PR Newswire
20 days ago
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
Simply Wall St.
22 days ago
Exploring High Growth Tech Stocks In The US Market
Insider Monkey
a month ago
Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025
PR Newswire
a month ago
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025
Simply Wall St.
2 months ago
Exploring 3 High Growth Tech Stocks in the United States
PR Newswire
3 months ago
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
Compare PGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PGEN Precigen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.